# **United States Securities and Exchange Commission**

Washington, D.C. 20549

# Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

(Amendment No. 3)\*

# Atea Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 (Title of Class of Securities)

04683R106 (CUSIP Number)

December 31, 2023 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	Names of Reporting Persons							
	JPM Partners LLC							
2								
	(a)							
3	SEC Use Only							
4	4 Citizenship or Place of Organization							
	Delaware							
Number of Shares		5	Sole Voting Power					
			0					
		6	Shared Voting Power					
Beneficially Owned by			5,925,000					
Each Reporting		7	Sole Dispositive Power					
Person			0					
With		8	Shared Dispositive Power					
			5,925,000					
9	Aggregate Amount Beneficially Owned by Each Reporting Person							
	5,925,000							
10								
	Not Applicable							
11								
	7.1%							
12	2 Type of Reporting Person							
	OO (Limited Liability Company)							

1	Names of Reporting Persons							
	Jean-Pierre Sommadossi							
2								
	(a)							
3	3 SEC Use Only							
4	4 Citizenship or Place of Organization							
	5. 1. F 8							
United States								
Number of Shares		5	Sole Voting Power					
			2,237,914					
		6	Shared Voting Power					
	eficially ned by		5,925,000					
Each Reporting		7	Sole Dispositive Power					
Person			2,237,914					
With		8	Shared Dispositive Power					
			5,925,000					
9	Aggregate Amount Beneficially Owned by Each Reporting Person							
	8,162,914							
10								
	Not Applicable							
11								
	9.6%							
12	2 Type of Reporting Person							
	IN							

#### ITEM 1. (a) Name of Issuer:

Atea Pharmaceuticals, Inc. (the "Issuer").

#### (b) Address of Issuer's Principal Executive Offices:

225 Franklin Street, Suite 2100, Boston, MA 02110.

#### ITEM 2. (a) Name of Person Filing:

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:

JPM Partners LLC; and

Jean-Pierre Sommadossi

#### (b) Address or Principal Business Office:

The business address of JPM Partners LLC is 2 Avery Street #21E, Boston, MA 02111. The business address of Dr. Sommadossi is c/o Atea Pharmaceuticals, Inc., 225 Franklin Street, Suite 2100, Boston, MA 02110.

#### (c) Citizenship:

JPM Partners LLC is a Delaware limited liability company. Dr. Sommadossi is a citizen of the United States.

#### (d) Title of Class of Securities:

Common stock, par value \$0.001 per share ("Common Stock").

#### (e) CUSIP Number:

04683R106

#### ITEM 3.

Not applicable.

#### ITEM 4. Ownership.

The ownership information below represents beneficial ownership of shares of Common Stock as of the date hereof, based upon 83,435,513 shares of Common Stock outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

(a-c)

					Sole	Shared
			Sole		power to	power to
			power	Shared	dispose or	dispose or
			to vote	power to	to direct	to direct
	Amount		or to	vote or to	the	the
	beneficially	Percent	direct	direct the	disposition	disposition
Reporting Person	owned	of class:	the vote:	vote:	of:	of:
JPM Partners LLC	5,925,000	7.1%	0	5,925,000	0	5,925,000
Jean-Pierre Sommadossi	8 162 914	9.6%	2 237 914	5 925 000	2 237 914	5 925 000

JPM Partners LLC is the record holder of 5,925,000 shares of Common Stock. Dr. Sommadossi is the manager of JPM Partners LLC and may be deemed to share beneficial ownership of the securities held by JPM Partner LLC. In addition, Dr. Sommadossi beneficially owns 2,237,914 shares of Common Stock, which includes 2,121,357 shares of Common Stock subject to stock options that are currently exercisable or will become exercisable within 60 days of the date hereof.

#### ITEM 5. Ownership of Five Percent or Less of a Class.

Not applicable.

#### ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

# ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

#### ITEM 8. Identification and Classification of Members of the Group.

Not applicable.

#### ITEM 9. Notice of Dissolution of Group.

Not applicable.

## ITEM 10. Certification.

Not applicable.

CUSIP No. 04683R106 Schedule 13G Page 6 of 7

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2024

#### JPM Partners LLC

By: /s/ Jean-Pierre Sommadossi

Name: Jean-Pierre Sommadossi

Title: Manager

#### Jean-Pierre Sommadossi

/s/ Jean-Pierre Sommadossi

CUSIP No. 04683R106 Schedule 13G Page 7 of 7

## LIST OF EXHIBITS

Exhibit No. Description

99 Joint Filing Agreement (previously filed).